Insurance coverage for GLP-1 drugs remains tight despite rising demand, with more patients facing restrictions or paying out ...

Novo Nordisk's Victoza (liraglutide) has become the only approved diabetes drug in the GLP-1 agonist class shown to demonstrate a cardiac safety benefit, although it faces competition from a ...

Victoza (liraglutide) and Ozempic (semaglutide) are two injectable drugs used to treat people with type 2 diabetes. The drugs, classified as GLP-1 agonists, have also been used for weight loss in ...

Czech Republic-based Zentiva Pharma, a generics and over-the-counter medicines company that is wholly-owned by private equity ...

Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a cheaper version of its key type 2 diabetes drug Victoza until 2023.

Victoza (liraglutide) is a prescription drug used to help manage type 2 diabetes and reduce the risk of certain diabetes-related heart problems. Victoza is given as a daily injection under the skin.

Biocon will market Liraglutide under two brand names - Liraglutide Biocon for diabetes, which is a generic version of Victoza ...

Novo Nordisk A/S (NOVO-B.KO) expects its closely-watched diabetes treatment Victoza to reach European customers in the nearest future, Chief Scientific Officer Mads Krogsgaard Thomsen said in an ...

Danish pharmaceutical company Novo Nordisk A/S (NOVO-B.KO) said Wednesday its drug Victoza has been shown in a clinical study to be more efficient than a competing drug in improving diabetes ...